Mark Goldberg

Mark Alan Goldberg currently works at Avacta Group Plc, as Independent Non-Executive Director from 2021 and Walden Biosciences, Inc., as Director.
Dr. Goldberg also formerly worked at ImmunoGen, Inc., as Independent Director from 2011 to 2024, Idera Pharmaceuticals, Inc., as Independent Director from 2014 to 2022, aTyr Pharma, Inc., as Director from 2015 to 2017, American Cancer Society, Inc., as Director from 2019 to 2023, American Cancer Society, New England Division, Inc., as Director from 2010 to 2017, Blueprint Medicines Corp., as Independent Director from 2015 to 2025, Astellas Gene Therapies, Inc., as Independent Director from 2017 to 2020, Aceragen, Inc., as Director, GlycoMimetics, Inc., as Independent Director from 2014 to 2025, Genzyme Corp., as Senior Vice President-Clinical Research from 1996 to 2011, Dana-Farber Cancer Institute, Inc., as Principal, The Brigham & Women's Hospital, Inc., as Principal, Harvard Medical School, as Associate Professor from 1996 to 2018, Synageva BioPharma Corp., as Executive VP-Global Medical & Regulatory Strategy from 2011 to 2014, and CANbridge Life Sciences Ltd., as Chief Medical Officer from 2015 to 2018.
Dr. Goldberg received his doctorate degree from Harvard Medical School and undergraduate degree from Harvard College.